Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127288041 | 12728804 | 1 | I | 20160303 | 20160315 | 20160909 | 20160909 | EXP | JP-CELGENEUS-JPN-2016035626 | CELGENE | 80.87 | YR | F | Y | 0.00000 | 20160909 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127288041 | 12728804 | 1 | PS | VIDAZA | AZACITIDINE | 1 | Intravenous drip | U | U | 50794 | 100 | MG | INJECTION | QD | |||||
| 127288041 | 12728804 | 2 | SS | VIDAZA | AZACITIDINE | 1 | Intravenous drip | U | U | 50794 | 100 | MG | INJECTION | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127288041 | 12728804 | 1 | Myelodysplastic syndrome |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127288041 | 12728804 | HO |
| 127288041 | 12728804 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127288041 | 12728804 | Sepsis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127288041 | 12728804 | 1 | 20150119 | 0 | ||
| 127288041 | 12728804 | 2 | 20160223 | 0 |